After the 3rd Council of Federations meeting, members of the EURORDIS Council of European Federations discussed the upper limits of orphan drug spending on a single rare disease patient. Participants represented a range of rare diseases (ex. epidermolysis bullosa, hereditary spastic paraplegia, myasthenia gravis, multiple myeloma, aniridia, osteogenisis imperfecta).
This is an overview of all sessions played at the event for which the results have been uploaded. Click on any session to see the votes on the policies.
| Decide Sessions | Topics |
|---|---|
| Council of European Rare Disease Federations discuss Cross border health care | Cross-border Health Care |
| Council of European Rare Disease Federations discuss Orphan drug expenditures | Orphan drugs |
FUND is a project funded by the European Commission (grant agreement SiS-CT-2009-230474). The views and opinions here expressed do not necessarily reflect those of the European Community and the Community is not liable for any use that may be made of the information contained therein.